SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 6

Evaluation of cardiometabolic function with serum adropin levels in psoriasis patients

Soner ÇANKAYA
Sevda ÖNDER
Tülin BAYRAK
Murat ÖZTÜRK
Yasemin KAYA
Pages
1118–1122
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no correlation between serum adropin level and other variables.Insulin level, Homa-IR level, systolic and diastolic pressure were significantly higher in the patient group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Psoriasis is a skin disease with metabolic and cardiac comorbidities.
📊
Key Findings & Data:In this study, we aimed toevaluate adropin levels in psoriasis patientsMaterials and Methods: The study included 51 plaque psoriasis patients aged 18-65 years who had no systemic disease and hadnot received systemic treatment in the last three months and 37 healthy controls matched by sex, age and body mass index (BMI).Serum adropin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), andtriglyceride (TG), fasting blood glucose (FBG), fasting serum insulin, BMI, systolic blood pressure (SBP) and diastolic blood pressure(DBP) values were recorded.Results: Serum adropin level was 73.04 ± 46.21 pg / ml in the patient group.
💡
Conclusion & Impact:There was no correlation between serum adropin level and other variables.Insulin level, Homa-IR level, systolic and diastolic pressure were significantly higher in the patient group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Psoriasis is a skin disease with metabolic and cardiac comorbidities. Adropin is a peptide hormone which is thought to play arole in metabolic diseases, energy homeostasis, endothelial function and cardiac diseases in recent years. In this study, we aimed toevaluate adropin levels in psoriasis patientsMaterials and Methods: The study included 51 plaque psoriasis patients aged 18-65 years who had no systemic disease and hadnot received systemic treatment in the last three months and 37 healthy controls matched by sex, age and body mass index (BMI).Serum adropin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), andtriglyceride (TG), fasting blood glucose (FBG), fasting serum insulin, BMI, systolic blood pressure (SBP) and diastolic blood pressure(DBP) values were recorded.Results: Serum adropin level was 73.04 ± 46.21 pg / ml in the patient group. In the control group, serum adropin level was 77.26 ±43.69 pg / ml. Serum adropin levels were lower in the patient group, but this was not statistically significant (p = 0.667). PASI valuewas negatively correlated with serum adropin level. There was no correlation between serum adropin level and other variables.Insulin level, Homa-IR level, systolic and diastolic pressure were significantly higher in the patient group (p

🔖

Cite This Article

ÇANKAYA, S., ÖNDER, S., BAYRAK, T., ÖZTÜRK, M., KAYA, Y. (2022). Evaluation of cardiometabolic function with serum adropin levels in psoriasis patients. Annals of Medical Research, Cilt: 28 - Sayı: 6, 1118–1122. https://ajindex.com/articles/445775

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol 2014;32:343-50
  2. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017;140:645-53
  3. Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci 2017;19:58
  4. Baran A, Myśliwiec H, Kiluk P, et al. Serum irisin levels in patients with psoriasis. J Dermatolog Treat 2017;28:304-8
  5. Baran A, Myśliwiec H, Szterling-Jaworowska M, et al. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatolog Treat. 2018;29:19-23
  6. Baran A, Świderska M, Myśliwiec H, et al. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels. J Dermatolog Treat 2017;28:136- 40
  7. Lovren F, Pan Yi, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122:185-92 8. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468-81
  8. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013;380: 73-81
  9. Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol 2014;41:310-2
  10. Sayain O, Tokgoz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2014;27:479-84
  11. Zhang S, Chen Q, Lin X, et al. A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation. Oxid Med Cell Longev 2020
  12. Gao Su, McMillan RP, Jacas J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014;63:3242-52
  13. Kume T, Calan M, Yilmaz O, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 2016; 39: 747-54
  14. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;41:375-80
  15. Sen H, Erbag G, Bınnetoglu E, et al. Adropin Levels in Polycystic Ovary Syndrome Patients. J Clin Anal Med 2017;8:23-6
  16. Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoria